20
Participants
Start Date
June 18, 2025
Primary Completion Date
May 31, 2026
Study Completion Date
December 31, 2027
STP938
At enrolment all patients will be assigned to a single dose level of STP938 for 4 weeks. After 4 weeks the dose level may be adjusted as needed by the Investigator.
NOT_YET_RECRUITING
CHU Brest, Brest
NOT_YET_RECRUITING
Institut Paoli-Calmettes, Marseille
NOT_YET_RECRUITING
CHU Nantes, Nantes
NOT_YET_RECRUITING
CHU Nice, Nice
RECRUITING
CHU Nîmes, Nîmes
RECRUITING
Hôpital Saint-Louis, Paris
NOT_YET_RECRUITING
Gustave Roussy, Villejuif
NOT_YET_RECRUITING
University Hospital of Wales, Cardiff
RECRUITING
Imperial College London / Hammersmith Hospital, London
RECRUITING
Sarah Cannon Research Institute, London
NOT_YET_RECRUITING
University of Southampton Hospital, Southampton
NOT_YET_RECRUITING
Cancer and Haematology Centre, Churchill Hospital, Oxford
Step Pharma, SAS
INDUSTRY